What common biomarkers characterize a triple-negative profile in breast cancer?

Triple-negative breast cancers are not a homogeneous subgroup. There is substantial intra-subgroup diversity in tumor biology, prognosis and treatment sensitivity. Then, these triple-negative phenotype (TNP) groups, having specific features, can be again divided into subclasses based on an added immunohistochemical markers. The challenge in treating TNP breast cancers is that they are not responsive to antiestrogens or trastuzumab secondary to negative receptor status, and as a result have a poor prognosis. Therefore, the presence or absence of supplementary markers could help predict which therapies are best suited for patients based on the pattern that their disease markers show. In this review, we will recapitulate the major supplementary biomarkers related to triple-negative breast cancer, which could give new therapeutic options.

RésuméLes cancers du sein triple négatifs ne représentent pas un sous-groupe homogène. Il existe une diversité substantielle intra-groupe dans la biologie de la tumeur, du pronostic et de la sensibilité au traitement. Ainsi, ces groupes de phénotype triple négatifs (TNP) possèdent des caractéristiques spécifiques leur permettant de se subdiviser en sous-classes en se basant sur d’autres marqueurs immuno-histochimiques. Le défi dans le traitement des cancers du sein au profil triple négatif ré